Search Results - "V. Ghisetti"

Hepatitis E: An emerging infection in high income countries by Arends, J.E, Ghisetti, V, Irving, W, Dalton, H.R, Izopet, J, Hoepelman, A.I.M, Salmon, D

“…Abstract Hepatitis E virus (HEV) genotype 3 is the most recently characterized hepatotropic virus and is increasingly being recognized as the cause of…”
Get full text

Hepatitis E Virus: A Cross‐Sectional Serological and Virological Study in Pigs and Humans at Zoonotic Risk within a High‐Density Pig Farming Area by Caruso, C., Peletto, S., Rosamilia, A., Modesto, P., Chiavacci, L., Sona, B., Balsamelli, F., Ghisetti, V., Acutis, P. L., Pezzoni, G., Brocchi, E., Vitale, N., Masoero, L.

“…Summary An increase in autochthonous hepatitis E virus (HEV) infections has been recorded in Italy suspected to be zoonotically transmitted from pigs; this…”
Get full text

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe by De Luca, Andrea, Dunn, David, Zazzi, Maurizio, Camacho, Ricardo, Torti, Carlo, Fanti, Iuri, Kaiser, Rolf, Sönnerborg, Anders, Codoñer, Francisco M., Van Laethem, Kristel, Vandamme, Anne-Mieke, Bansi, Loveleen, Ghisetti, Valeria, van de Vijver, David A. M. C., Asboe, David, Prosperi, Mattia C. F., Di Giambenedetto, Simona

“…HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in…”
Get full text

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen by Armenia, D, Di Carlo, D, Calcagno, A, Vendemiati, G, Forbici, F, Bertoli, A, Berno, G, Carta, S, Continenza, F, Fedele, V, Bellagamba, R, Cicalini, S, Ammassari, A, Libertone, R, Zaccarelli, M, Ghisetti, V, Andreoni, M, Ceccherini-Silberstein, F, Bonora, S, Di Perri, G, Antinori, A, Perno, C F, Santoro, M M

“…To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a…”
Get full text

Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes by Boglione, L., D'Avolio, A., Cariti, G., Milia, M. G., Simiele, M., De Nicolò, A., Ghisetti, V., Di Perri, G.

“…Summary Complete eradication of hepatitis B virus (HBV) is rarely achieved. Treatment options include currently available nucleos(t)ide analogues and pegylated…”
Get full text

Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? by Mornese Pinna, S., Scarvaglieri, E., Milia, M. G., Imperiale, D., Ghisetti, V., Audagnotto, S., Prochet, A., Lipani, F., Bonora, S., Di Perri, G., Calcagno, A

“…In the absence of effective prophylaxis and treatment, therapeutic options in HIV-positive patients with progressive multifocal leukoencephalopathy (PML) are…”
Get full text

Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy by Calcagno, A, Trentini, L, Marinaro, L, Montrucchio, C, D'Avolio, A, Ghisetti, V, Di Perri, G, Bonora, S

Get full text

Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus by Allice, Tiziano, Busca, Alessandro, Locatelli, Franco, Falda, Michele, Pittaluga, Fabrizia, Ghisetti, Valeria

“…Objectives Valganciclovir is a well established drug for the management of cytomegalovirus (CMV) infection in haematopoietic stem cell transplantation (HSCT)…”
Get full text

Appropriate diagnosis of Zika virus infection: Italy North-West experience by Burdino, E, Allice, T, Milia, M.G, Gregori, G, Ruggiero, T, Calleri, G, Lipani, F, Lucchini, A, Venturi, G, Ghisetti, V

Get full text

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing by Ruggiero, T., Burdino, E., Calcagno, A., Bonora, S., Boglione, L., Di Perri, G., Ghisetti, V.

“…Purpose Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods NS3-HCV…”
Get full text

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy by Boglione, L., De Nicolò, A., Cardellino, C.S., Ruggiero, T., Ghisetti, V., Cariti, G., Di Perri, G., D'Avolio, A.

“…In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the…”
Get full text

A one-year survey of carbapenemase-producing Klebsiella pneumoniae in Italy: beyond the ICU by Corcione, S., Rocchetti, A., Argentero, P.A., Raso, R., Zotti, C.M., De Rosa, F.G., Ghisetti, V.

Get full text

Prevalence and predictors of blood-brain barrier damage in the HAART era by Calcagno, A., Alberione, M. C., Romito, A., Imperiale, D., Ghisetti, V., Audagnotto, S., Lipani, F., Raviolo, S., Di Perri, G., Bonora, S.

“…Blood-brain barrier damage (BBBD) is prevalent in HIV-positive patients and may enhance cell trafficking to the central nervous system. A retrospective…”
Get full text

Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis by Calcagno, A., Romito, A., Atzori, C., Ghisetti, V., Cardellino, C., Audagnotto, S., Scarvaglieri, E., Lipani, F., Imperiale, D., Di Perri, G., Bonora, S.

“…Blood brain barrier (BBB) damage is a common feature in central nervous system infections by HIV and it may persist despite effective antiretroviral therapy…”
Get full text

Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients by Calcagno, A., Marinaro, L., Nozza, S., Aldieri, C., Carbone, A., Ghisetti, V., Trentalange, A., D’Avolio, A., Castagna, A., Di Perri, G., Bonora, S.

“…•Higher etravirine concentrations and weighted genetic inhibitory quotients are associated with virological success.•We propose here two possible targets…”
Get full text

Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoeae in Italy from 2006 to 2010 by Carannante, A., Prignano, G., Cusini, M., Matteelli, A., Dal Conte, I., Ghisetti, V., D'Antuono, A., Cavrini, F., Antonetti, R., Stefanelli, P.

“…Neisseria gonorrhoeae resistance to cephalosporins, the currently recommended treatment, and treatment failures with cefixime have been reported worldwide. The…”
Get full text

Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients by Calcagno, A, Nozza, S, Simiele, M, Milia, M G, Chiappetta, S, D'Avolio, A, Ghisetti, V, Lazzarin, A, Di Perri, G, Bonora, S

Get full text

Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation by Busca, A., De Fabritiis, P., Ghisetti, V., Allice, T., Mirabile, M., Gentile, G., Locatelli, F., Falda, M.

“…: Antiviral compounds including ganciclovir, foscarnet, and cidofovir are routinely used in the treatment of cytomegalovirus (CMV) infection and disease;…”
Get full text

HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life by Cento, V, Barbaliscia, S, Lenci, I, Ruggiero, T, Masetti, C, Magni, C.F, Micheli, V, Paolucci, S, Troshina, Y, Biliotti, E, Milana, M, Melis, M, Teti, E, Lambiase, L, Menzaghi, B, Nicolini, L.A, Marenco, S, Di Maio, V.C, Aragri, M, Pecchioli, A, Bertoli, A, Antonucci, F.P, Sarmati, L, Sarrecchia, C, Macera, M, Coppola, N, Danieli, E, Romagnoli, D, Pellicelli, A, Bonora, S, Babudieri, S, Di Biagio, A, Picciotto, A, Novati, S, Siciliano, M, Messina, V, Claar, E, Baldanti, F, Pasquazzi, C, Ciancio, A, Puoti, M, Ghisetti, V, Andreoni, M, Taliani, G, Rizzardini, G, Angelico, M, Perno, C.F, Ceccherini-Silberstein, F

Get full text

The effect of antituberculosis treatment on interferon-gamma release assay results by Bugiani, M, Bonora, S, Carosso, A, Piccioni, P, Cavallero, M, Mondo, A, Ghisetti, V

“…Monitoring the efficacy of antituberculosis therapy is crucial. The aim of this work is to investigate the effect of tuberculosis treatment on interferon-gamma…”
Get full text